Tao Yilin, Luo Ruixiang, Xiang Yuanbing, Lei Min, Peng Xuan, Hu Yao
Department of Medicine Renal Division, Affiliated Hospital & Clinical Medical College of Chengdu University, Chengdu, China.
The Third Affiliated Hospital of Sun Yat Sen University, Guangzhou, China.
Front Pharmacol. 2024 Apr 5;15:1342831. doi: 10.3389/fphar.2024.1342831. eCollection 2024.
The Bailing Capsule is a commonly used traditional Chinese medicine for the treatment of chronic kidney disease (CKD). However, its therapeutic effects and pharmacological mechanisms have not been fully explored. In this study, we integrated meta-analysis and network pharmacology to provide scientific evidence for the efficacy and pharmacological mechanism of Bailing Capsule in treating CKD. We conducted searches for randomized controlled studies matching the topic in PubMed, the Cochrane Library, Embase, Web of Science, and the Wanfang Database, and screened them according to predefined inclusion and exclusion criteria. Dates from the included studies were extracted for meta-analysis, including renal function indicators, such as 24-h urinary protein (24UP), blood urea nitrogen (BUN), and serum creatinine (Scr), as well as inflammatory indicators like high-sensitivity C-reactive protein (hs-CRP), interleukin-6 (IL-6), and tumor necrosis factor-alpha (TNF-α). Network pharmacology was employed to extract biological information, including active drug ingredients and potential targets of the drugs and diseases, for network construction and gene enrichment. Our findings indicated that 24UP, BUN, and Scr in the treatment group containing Bailing Capsule were lower than those in the control group. In terms of inflammatory indicators, hs-CRP, IL-6, and TNF-α, the treatment group containing Bailing Capsule also exhibited lower levels than the control group. Based on network pharmacology analysis, we identified 190 common targets of Bailing Capsule and CKD. Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) analyses suggested that the pharmacological mechanism of Bailing Capsule might be related to immune response, inflammatory response, vascular endothelial damage, cell proliferation, and fibrosis. This demonstrates that Bailing Capsule can exert therapeutic effects through multiple targets and pathways, providing a theoretical basis for its use.
百令胶囊是治疗慢性肾脏病（CKD）常用的一种中药。然而，其治疗效果和药理机制尚未得到充分探索。在本研究中，我们综合运用荟萃分析和网络药理学，为百令胶囊治疗CKD的疗效和药理机制提供科学依据。我们在PubMed、Cochrane图书馆、Embase、Web of Science和万方数据库中检索了与该主题匹配的随机对照研究，并根据预先设定的纳入和排除标准进行筛选。提取纳入研究的数据进行荟萃分析，包括肾功能指标，如24小时尿蛋白（24UP）、血尿素氮（BUN）和血清肌酐（Scr），以及炎症指标，如高敏C反应蛋白（hs-CRP）、白细胞介素-6（IL-6）和肿瘤坏死因子-α（TNF-α）。运用网络药理学提取生物学信息，包括药物和疾病的活性成分及潜在靶点，用于构建网络和基因富集分析。我们的研究结果表明，含百令胶囊的治疗组中24UP、BUN和Scr低于对照组。在炎症指标方面，含百令胶囊的治疗组中hs-CRP、IL-6和TNF-α水平也低于对照组。基于网络药理学分析，我们确定了百令胶囊和CKD的190个共同靶点。基因本体（GO）和京都基因与基因组百科全书（KEGG）分析表明，百令胶囊的药理机制可能与免疫反应、炎症反应、血管内皮损伤、细胞增殖和纤维化有关。这表明百令胶囊可通过多个靶点和途径发挥治疗作用，为其应用提供了理论依据。
Zotero 插件
